Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Update

Evaxion Biotech A/S (NASDAQ:EVAX) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 22,400 shares, a decrease of 74.2% from the February 28th total of 86,700 shares. Based on an average daily volume of 2,260,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 2.1% of the company’s stock are short sold.

Evaxion Biotech A/S Price Performance

Shares of Evaxion Biotech A/S stock remained flat at $1.76 during trading on Friday. The company had a trading volume of 39,037 shares, compared to its average volume of 594,950. Evaxion Biotech A/S has a 12 month low of $1.67 and a 12 month high of $22.05. The stock has a 50-day simple moving average of $2.49 and a 200-day simple moving average of $7.29. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. The stock has a market cap of $2.06 million, a PE ratio of -1.21 and a beta of -0.25.

Wall Street Analysts Forecast Growth

EVAX has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Evaxion Biotech A/S in a research note on Thursday, February 20th. Lake Street Capital decreased their price objective on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, February 4th.

Institutional Trading of Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC bought a new position in Evaxion Biotech A/S (NASDAQ:EVAX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned about 2.98% of Evaxion Biotech A/S at the end of the most recent quarter. 11.04% of the stock is currently owned by institutional investors and hedge funds.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.